Analyzing IL-23 Inhibitors in Psoriasis

This episode, titled "Analyzing IL-23 Inhibitors in Psoriasis," features panelists discussing the future of IL-23 targeted therapies and the practical considerations surrounding the anticipated shift toward oral treatment options in plaque psoriasis.

The panel opens by surveying the emerging therapeutic pipeline, noting that most innovations continue to target the IL-23 pathway either directly or indirectly, underscoring the cytokine's central role in psoriasis pathogenesis. Key agents discussed include an oral macrocyclic peptide IL-23 receptor blocker, which directly binds the receptor rather than the cytokine and has demonstrated complete skin clearance in approximately half of patients at 24 weeks, a level of efficacy described as unprecedented for an oral therapy and comparable to leading biologics. Two next generation TYK2 inhibitors are also highlighted, offering higher binding affinity and selectivity than existing options and indirectly antagonizing IL-23 signaling with more rapid and deeper responses. Additionally, a monoclonal antibody called ORKA-001 is discussed, notable for its half-life approximately four times greater than risankizumab and its potential for dosing intervals of every 6 to 12 months in responding patients.

From a safety standpoint, the panel notes that IL-23 targeted therapies continue to demonstrate a favorable profile, with only occasional mild adverse events such as upper respiratory tract infections or fungal infections.

The discussion then shifts to the practical implications of oral versus injectable IL-23 therapies in real world settings. The panel acknowledges that while clinical trials demonstrate strong efficacy for emerging oral agents, real world adherence remains an open question, with concerns around daily pill taking, administration requirements such as empty stomach dosing, and potential drug interactions. Injectable biologics are noted as having a relative adherence advantage given their infrequent dosing schedule and easier monitoring. The panel agrees that needle phobia, while real for some patients, affects a smaller population than commonly assumed, particularly when injections are spaced weeks or months apart. Ultimately, the panel expresses enthusiasm for expanded treatment options, emphasizing that real world evidence will be critical in determining how well emerging oral therapies perform outside of controlled trial settings.

In the next episode, "Value of Utilizing Matching-Adjusted Indirect Comparisons (MAICs) in Psoriasis," panelists will continue their discussion on psoriasis and highlight the methodology and clinical value of matching adjusted indirect comparisons as a rigorous statistical tool for comparing biologic therapies in the absence of head to head trial data, and how this evidence can inform treatment sequencing decisions in real world practice.